The Tulane Blood Cancer Program, a Sarah Cannon Blood Cancer Network partner, is committed to advancing the science and care of patients with blood cancers such as leukemia, lymphoma and myeloma. Alongside the Tulane University School of Medicine, we have performed more than 400 life-saving blood and bone marrow transplants, and we are a leader in the New Orleans region as the first fully accredited Foundation for Accreditation of Cellular Therapy (FACT) facility in Louisiana. Our experienced hematologists and multi-disciplinary team creates individualized treatment plans for each patient, and we have access to the latest clinical trials and therapies.
What Sets Us Apart
- We are a Sarah Cannon Blood Cancer Network partner, one of the largest providers of blood cancer care including blood and marrow transplantation (BMT) across the United States and United Kingdom. Through its commitment to the highest level of quality standards, infrastructure, training and research, the Sarah Cannon Blood Cancer Network provides an unparalleled experience for patients seeking treatment.
- We are the first FACT-accredited adult center in the state of Louisiana for both autologous and allogeneic transplants, performing related and unrelated donor transplants. FACT is the global standard for top-quality patient care in cellular therapies.
- We are the only National Marrow Donor Program (NMDP) transplant, apheresis and collection center for adults in Louisiana.
The Tulane Blood Cancer Program treats patients with a wide variety of conditions, including:
- Autoimmune disease
- Aplastic anemia
- Acute myeloblastic and lymphoblastic leukemia
- Chronic myelogenous leukemia
- Chronic lymphocytic leukemia
- Multiple myeloma
- Myelodysplastic Syndrome (MDS)
- Non-Hodgkin's lymphoma
- Hodgkin's disease
- Germ cell carcinoma
- Ewing's sarcoma
- Other non-malignant hematologic diseases
Types of Transplants Offered
- Autologous - patient serves as his or her own donor
- Allogeneic - another person serves as the patient’s donor
- Syngeneic - an identical twin serves as the patient’s donor
- Myeloablative and non-myeloablative transplants